Lloyd j. Old

Q: What Schools Are Affiliated With Lloyd j. Old

Lloyd j. Old is affiliated with the following schools: Mie University, Cornell University, Okayama University, Tokyo Medical University, New York University, Leiden University, Saarland University, University of Lausanne, University of Oxford, Albert Einstein College of Medicine, Istanbul University, Icahn School of Medicine at Mount Sinai

Lloyd j. Old's AcademicInfluence.com Rankings

Lloyd j. Old

Medical

#240

World Rank

#357

Historical Rank

Oncology

World Rank

Historical Rank

medical Degrees

Lloyd j. Old

Biology

#1268

World Rank

#2151

Historical Rank

Immunology

#29

World Rank

#32

Historical Rank

biology Degrees

Download Badge

Medical
Biology

Lloyd j. Old's Degrees

Masters Medicine Columbia University

Why Is Lloyd j. Old Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lloyd j. Old's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion (2011) (4980)
Cancer immunoediting: from immunosurveillance to tumor escape (2002) (4573)
An endotoxin-induced serum factor that causes necrosis of tumors. (1975) (4515)
The three Es of cancer immunoediting. (2004) (2682)
The immunobiology of cancer immunosurveillance and immunoediting. (2004) (2613)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity (2001) (2524)
Tumor necrosis factor (TNF). (1985) (2429)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. (2005) (2181)
Cancer/testis antigens, gametogenesis and cancer (2005) (1495)
Adaptive immunity maintains occult cancer in an equilibrium state (2007) (1316)
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice (1998) (1284)
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. (1997) (1278)
Antibody therapy of cancer (2012) (1141)
Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting (2012) (1076)
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy (2002) (865)
Characterization of tumor necrosis factor-deficient mice. (1997) (841)
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. (1998) (783)
Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes (1998) (759)
A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens (1998) (745)
The cancer/testis genes: review, standardization, and commentary. (2004) (714)
Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. (1979) (714)
The roles of IFNγ in protection against tumor development and cancer immunoediting (2002) (711)
A new class of murine leukemia virus associated with development of spontaneous lymphomas. (1977) (701)
Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer (2010) (686)
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. (1994) (666)
Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. (1990) (605)
TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination (1998) (584)
ANTIGENIC PROPERTIES OF CHEMICALLY INDUCED TUMORS * (1962) (579)
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. (1985) (565)
GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody (1982) (546)
Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. (1980) (533)
Improved Endpoints for Cancer Immunotherapy Trials (2010) (511)
NKT Cells Enhance CD4+ and CD8+ T Cell Responses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells 1 (2003) (506)
Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts* (1999) (498)
Tumor rejection antigens of chemically induced sarcomas of inbred mice. (1986) (491)
Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. (1994) (485)
The roles of IFN gamma in protection against tumor development and cancer immunoediting. (2002) (484)
New Paths in Human Cancer Serology (1998) (479)
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma (2007) (464)
Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. (1991) (463)
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. (2004) (460)
PRECIPITATING ANTIBODY IN HUMAN SERUM TO AN ANTIGEN PRESENT IN CULTURED BURKITT'S LYMPHOMA CELLS* (1966) (455)
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. (2000) (455)
Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse (1959) (441)
Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. (1983) (425)
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. (1976) (421)
Some Aspects of Normal and Abnormal Cell Surface Genetics (1969) (420)
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. (2000) (420)
Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. (1981) (387)
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. (2000) (373)
GENETIC BASIS OF SUSCEPTIBILITY TO VIRAL LEUKAEMOGENESIS. (1964) (364)
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. (2003) (362)
Characterization of human colon cancer antigens recognized by autologous antibodies (1998) (354)
Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues (2001) (351)
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. (2007) (350)
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets (1982) (350)
The role of the reticuloendothelial system in the host reaction to neoplasia. (1961) (344)
CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens (2008) (338)
NY-ESO-1: review of an immunogenic tumor antigen. (2006) (336)
Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer (2005) (336)
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit (2008) (335)
CD8+ Foxp3+ Regulatory T Cells Mediate Immunosuppression in Prostate Cancer (2007) (334)
Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? (1984) (333)
Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. (1998) (328)
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab (2011) (323)
Genome-wide analysis of cancer/testis gene expression (2008) (315)
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming (2007) (312)
Inhibition of leukemias in man by L-asparaginase. (1967) (306)
Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. (1993) (303)
Horizontal Transmission of Feline Leukaemia Virus (1973) (275)
SEROLOGICALLY DEMONSTRABLE ALLOANTIGENS OF MOUSE EPIDERMAL CELLS (1972) (273)
Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. (1984) (273)
ANTIGENS OF LEUKEMIAS INDUCED BY NATURALLY OCCURRING MURINE LEUKEMIA VIRUS: THEIR RELATION TO THE ANTIGENS OF GROSS VIRUS AND OTHER MURINE LEUKEMIA VIRUSES (1966) (271)
Colon cancer associated transcript‐1: A novel RNA expressed in malignant and pre‐malignant human tissues (2012) (269)
SURFACE ALLOANTIGENS OF PLASMA CELLS (1970) (258)
ANTIGENIC MODULATION (1968) (258)
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer (2007) (255)
Ly-A and Ly-B: two systems of lymphocyte isoantigens in the mouse (1968) (254)
Cancer immunology: the search for specificity. (1982) (254)
The G (Gross) leukemia antigen. (1965) (252)
SSX: A multigene family with several members transcribed in normal testis and human cancer (1997) (250)
Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. (1999) (250)
Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma (2000) (249)
The G-IX system. A cell surface allo-antigen associated with murine leukemia virus; implications regarding chromosomal integration of the viral genome. (1971) (247)
PEGylated gold nanoparticles conjugated to monoclonal F19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue. (2008) (246)
Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. (1995) (245)
Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells. (1982) (245)
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. (2003) (243)
Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon (1984) (238)
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients (2012) (237)
Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant1 (2008) (237)
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. (1987) (234)
Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. (1986) (230)
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses (2003) (230)
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. (1984) (229)
Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. (2000) (228)
Two L-asparaginases from Escherichia coli B. Their separation, purification, and antitumor activity. (1967) (228)
Effect of tumour necrosis factor on cultured human melanoma cells (1975) (219)
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens (1981) (219)
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients (2006) (218)
ANTIGENIC PROPERTIES OF EXPERIMENTAL LEUKEMIAS. I. SEROLOGICAL STUDIES IN VITRO WITH SPONTANEOUS AND RADIATION-INDUCED LEUKEMIAS. (1963) (218)
Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. (1986) (216)
Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. (1996) (216)
Expression of MAGE‐antigens in normal tissues and cancer (2000) (216)
A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. (1998) (215)
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. (1994) (214)
Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. (2001) (214)
CYTOTOXIC TEST FOR DEMONSTRATION OF MOUSE ANTIBODY. (1964) (214)
Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera. (1979) (212)
Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. (1992) (211)
Cell cycle-specific effects of tumor necrosis factor. (1984) (210)
Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. (1988) (208)
Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. (1998) (207)
Cancer/testis (CT) antigens - a new link between gametogenesis and cancer. (2001) (207)
Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma (1977) (207)
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors (2007) (206)
Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. (1998) (204)
Expression of T-cell differentiation antigens on effector cells in cell- mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells (1975) (202)
Tumor necrosis factor. (1988) (199)
Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. (2001) (199)
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. (2005) (196)
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. (1994) (195)
Tumour necrosis factor. Polypeptide mediator network. (1987) (194)
Antigens recognized by autologous antibody in patients with renal‐cell carcinoma (1999) (194)
Asparagine Synthetase Activity of Mouse Leukemias (1968) (194)
"MIATA"-minimal information about T cell assays. (2009) (193)
The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. (1997) (192)
Expression of SSX genes in human tumors (1998) (192)
LEUKEMIA-ASSOCIATED TRANSPLANTATION ANTIGENS RELATED TO MURINE LEUKEMIA VIRUS (1973) (191)
Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. (1993) (190)
THE RETICULOENDOTHELIAL SYSTEM AND THE NEOPLASTIC PROCESS * (1960) (190)
CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. (2005) (186)
Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. (2002) (185)
IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. (2005) (184)
Serological analysis of cell surface antigens of malignant human brain tumors. (1978) (184)
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny‐eso‐1 but not mage‐a1 or ct7 (2001) (183)
and shape tumour immunogenicity (2001) (183)
Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients1 (2004) (183)
Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL1 (2000) (180)
p53 transformation-related protein: detection by monoclonal antibody in mouse and human cells. (1981) (179)
CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses (2003) (178)
Immunogenetics of cell surface antigens of mouse leukemia. (1977) (178)
IMMUNOGLOBULIN AND OTHER SURFACE ANTIGENS OF CELLS OF THE IMMUNE SYSTEM (1971) (177)
Antigenic structure of cell surfaces, an immunoferritin study of the occurrence and topography of h-2, theta, and tl alloantigens on mouse cells. (1969) (176)
A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. (1994) (176)
Seromic profiling of ovarian and pancreatic cancer (2010) (174)
Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. (1995) (174)
Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. (2001) (173)
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients (2012) (173)
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor (2003) (172)
Coordinate changes in neuronal phenotype and surface antigen expression in human neuroblastoma cell variants. (1987) (171)
Establishment and characterization of human renal cancer and normal kidney cell lines. (1990) (170)
In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. (2006) (168)
Generation of human monoclonal antibodies reactive with cellular antigens. (1983) (168)
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. (2007) (164)
Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. (1988) (164)
Modification of the antigenic structure of the cell membrane by thymus-leukemia (TL) antibody. (1967) (163)
An approach to the mapping of antigens on the cell surface. (1968) (162)
Transferable anticancer innate immunity in spontaneous regression/complete resistance mice (2006) (162)
Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells (1987) (161)
Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. (1985) (159)
Trisomy of chromosome 15 in spontaneous leukemia of AKR mice. (1975) (159)
Changes in expression of murine leukemia virus antigens and production of xenotropic virus in the late preleukemic period in AKR mice. (1976) (157)
Cell surface antigens of human renal cancer defined by autologous typing (1979) (157)
Expression of p21ras in normal and malignant human tissues: lack of association with proliferation and malignancy. (1987) (156)
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming (2008) (156)
Humoral immune responses of cancer patients against “Cancer‐Testis” antigen NY‐ESO‐1: Correlation with clinical events (1999) (156)
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. (1998) (155)
Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. (1987) (155)
Defining the critical hurdles in cancer immunotherapy (2011) (152)
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma (2013) (150)
Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study (2010) (149)
Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. (2001) (149)
Cell surface antigens of human renal cancer defined by mouse monoclonal antibodies: identification of tissue-specific kidney glycoproteins. (1981) (148)
Immunohistochemical analysis of nerve growth factor receptor expression in normal and malignant human tissues. (1988) (146)
Human homologue of murine tumor rejection antigen gp96: 5'-regulatory and coding regions and relationship to stress-induced proteins. (1990) (145)
Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. (1996) (143)
Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours (2000) (143)
Identification of cancer/testis genes by database mining and mRNA expression analysis (2002) (142)
Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. (2009) (140)
The SSX gene family: Characterization of 9 complete genes (2002) (139)
Cell-mediated cytotoxicity for bladder carcinoma: evaluation of a workshop. (1975) (138)
Partial purification of a serum factor that causes necrosis of tumors. (1976) (138)
Novel monoclonal antibody specific for the de2‐7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene (2002) (137)
Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. (1999) (136)
USE OF HYBRID ANTIBODY WITH ANTI-γG AND ANTI-FERRITIN SPECIFICITIES IN LOCATING CELL SURFACE ANTIGENS BY ELECTRON MICROSCOPY (1968) (136)
Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: Basis for polyvalent CT vaccine strategies (1998) (136)
Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3. (1998) (136)
Tumor necrosis factor α plays a central role in immune-mediated clearance of adenoviral vectors (1997) (135)
Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells (2005) (134)
T cell assays and MIATA: the essential minimum for maximum impact. (2012) (134)
Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. (2000) (133)
Human melanoma antigen AH is an autoantigenic ganglioside related to GD2 (1982) (132)
A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. (1994) (132)
Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. (1993) (132)
Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. (1999) (131)
Cooverexpression of chaperones for enhanced secretion of a single-chain antibody fragment in Pichia pastoris (2007) (131)
Expression of Ia-like antigens on cultured human malignant melanoma cell lines. (1978) (131)
Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. (1989) (129)
G (Gross) and H-2 cell-surface antigens: location on Gross leukemia cells by electron microscopy with visually labeled antibody. (1970) (128)
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals (2010) (128)
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. (2007) (128)
SUPPRESSION OF MURINE LEUKEMIAS BY L-ASPARAGINASE INCIDENCE OF SENSITIVITY AMONG LEUKEMIAS OF VARIOUS TYPES: COMPARATIVE INHIBITORY ACTIVITIES OF GUINEA PIG SERUM L-ASPARAGINASE AND ESCHERICHIA COLI L-ASPARAGINASE (1967) (127)
Shared Viral Antigen of Mammalian Leukaemia Viruses (1970) (126)
Monoclonal Antibodies Detect Occult Breast Carcinoma Metastases in the Bone Marrow of Patients with Early Stage Disease (1988) (125)
Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. (2001) (125)
Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor* (2004) (124)
An optimized fermentation process for high-level production of a single-chain Fv antibody fragment in Pichia pastoris. (2004) (123)
Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. (2005) (123)
CT10: A new cancer‐testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational‐difference analysis (2000) (123)
Humoral immune responses in patients vaccinated with 1–146 HER2 protein complexed with cholesteryl pullulan nanogel (2008) (123)
T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. (2007) (122)
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma (2013) (121)
Identification of cancer/testis-antigen genes by massively parallel signature sequencing (2005) (121)
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. (2000) (120)
Human monoclonal antibodies to glycolipids and other carbohydrate antigens: dissection of the humoral immune response in cancer patients. (1989) (120)
Serologic approaches to the study of cancer in animals and in man. (1968) (118)
The Rabbit Antibody Repertoire as a Novel Source for the Generation of Therapeutic Human Antibodies* (2000) (118)
Occurrence of natural antibody to the G (gross) leukemia antigen in mice. (1966) (118)
IMMUNOLOGY OF EXPERIMENTAL TUMORS. (1964) (117)
A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake (2005) (117)
Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics (1977) (116)
Pigmentation-associated glycoprotein of human melanomas and melanocytes: definition with a mouse monoclonal antibody. (1985) (116)
Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen (2001) (116)
Immunomic analysis of human sarcoma (2003) (115)
Antigens of tumors and leukemias induced by viruses. (1965) (115)
Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. (1987) (114)
Corynebacterium parvum as the priming agent in the production of tumor necrosis factor in the mouse. (1977) (113)
Tumor‐reactive CD8+ T‐cell responses after vaccination with NY‐ESO‐1 peptide, CpG 7909 and Montanide® ISA‐51: association with survival (2009) (112)
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma (1983) (110)
Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. (1985) (110)
Cancer immunoediting: from immuno- surveillance to tumor escape (2002) (109)
Individually distinct transplantation antigens of chemically induced mouse tumors. (1988) (109)
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity. (1985) (109)
Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. (1997) (109)
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. (2004) (107)
Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor (1986) (107)
Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. (1989) (107)
Rejection of Skin Allografts by Radiation Chimaeras: Selective Gene Action in the Specification of Cell Surface Structure (1970) (107)
Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity (2011) (106)
High-molecular-weight glycoproteins of human teratocarcinoma defined by monoclonal antibodies to carbohydrate determinants. (1985) (105)
Leukemogenic properties of AKR dualtropic (MCF) viruses: amplification of murine leukemia virus-related antigens on thymocytes and acceleration of leukemia development in AKR mice. (1981) (105)
HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan (2006) (105)
Fibroblast activation protein: Purification, epitope mapping and induction by growth factors (1994) (105)
Mouse Leukæmias: Typing of Mouse Leukæmias by Serological Methods (1964) (104)
SOME FURTHER DATA ON CYTOTOXIC ISOANTIBODIES IN THE MOUSE * (1962) (103)
Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. (2000) (103)
Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. (1989) (102)
GENETIC LINKAGE RELATIONSHIPS OF LOCI SPECIFYING DIFFERENTIATION ALLOANTIGENS IN THE MOUSE (1972) (102)
CT-X antigen expression in human breast cancer (2009) (101)
Antigenic Properties of Experimental Leukemias. II. Immunological Studies In Vivo With C57BL/6 Radiation-Induced Leukemias (1963) (101)
Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor–Specific Antibody Generates Enhanced Antitumor Activity (2005) (101)
Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. (1982) (101)
Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. (1997) (101)
Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478 (2003) (101)
Bioinformatics construction of the human cell surfaceome (2009) (100)
Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. (1991) (99)
T cell functions in granulocyte/macrophage colony-stimulating factor deficient mice. (1997) (98)
IFN-γ Controls the Generation/Activation of CD4+CD25+ Regulatory T Cells in Antitumor Immune Response1 (2005) (98)
A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. (1990) (97)
Oncogenomics and the development of new cancer therapies (2004) (97)
Growth regulation of human melanocytes: mitogenic factors in extracts of melanoma, astrocytoma, and fibroblast cell lines. (1985) (96)
Common properties of the oncogenic RNA viruses (oncornaviruses). (1970) (96)
Specificity analysis of blood group Lewis-y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants. (1994) (95)
Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations (2002) (94)
Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. (1988) (94)
Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. (2002) (93)
Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets. (1986) (93)
Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission (2008) (92)
Expression of cancer/testis (CT) antigens in lung cancer. (2003) (92)
Rapid evolution of cancer/testis genes on the X chromosome (2007) (92)
Cell-surface antigens of melanoma recognized by human monoclonal antibodies. (1987) (91)
Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. (2004) (91)
A HISTOCHEMICAL STUDY OF ACID AND ALKALINE PHOSPHATASE IN MOUSE LIVERS DURING VARIOUS CONDITIONS MODIFYING ACTIVITY OF THE RETICULOENDOTHELIAL SYSTEM (1961) (91)
Tumor necrosis factor. (1988) (91)
Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. (1994) (90)
Cancer-testis antigens: targets for cancer immunotherapy. (1999) (90)
NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors (2004) (90)
Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase (2011) (90)
Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein. (2005) (89)
CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases (2011) (89)
Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma. (1987) (89)
CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients (2002) (89)
Multiple Cancer/Testis Antigens Are Preferentially Expressed in Hormone-Receptor Negative and High-Grade Breast Cancers (2011) (89)
Suspension culture of a pigment-producing cell line derived from a human malignant melanoma. (1968) (88)
Blood group-related antigens in human urothelium: enhanced expression of precursor, LeX, and LeY determinants in urothelial carcinoma. (1988) (88)
Class II histocompatibility antigen expression in human melanocytes transformed by Harvey murine sarcoma virus (Ha-MSV) and Kirsten MSV retroviruses (1986) (88)
Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. (2008) (88)
Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. (1992) (87)
Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes (2004) (87)
Kinetic analysis of the interaction between the monoclonal antibody A33 and its colonic epithelial antigen by the use of an optical biosensor. A comparison of immobilisation strategies. (1997) (87)
MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin (2011) (87)
Phase I study of anticolon cancer humanized antibody A33. (2003) (86)
Serological cloning of a melanocyte rab guanosine 5'-triphosphate-binding protein and a chromosome condensation protein from a melanoma complementary DNA library. (2000) (86)
Isolation and some characteristics of a group-specific antigen of the murine leukemia viruses. (1969) (86)
Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma (2006) (86)
High affinity binding of 125I-labeled human tumor necrosis factor (LuKII) to specific cell surface receptors (1985) (86)
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. (2009) (85)
Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. (2001) (85)
Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. (1996) (83)
PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. (2007) (83)
Treatment of lymphosarcoma in the dog with L‐asparaginase (1967) (83)
124I-huA33 Antibody PET of Colorectal Cancer (2011) (83)
Delayed Hypersensitivity and Transplantation Immunity elicited by Soluble Antigens of Chemically Induced Tumours in Inbred Guinea-pigs (1968) (83)
Expression of human nerve growth factor receptor on cells derived from all three germ layers. (1988) (82)
Age-related changes in cell surface antigens of preleukemic AKR thymocytes (1976) (82)
Feline Leukemia Virus: Occurrence of Viral Antigen in the Tissues of Cats with Lymphosarcoma and Other Diseases (1969) (82)
Mouse fibroblast activation protein: Molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers (1997) (81)
Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. (2009) (81)
A murine monoclonal antibody detecting N-acetyl- and N-glycolyl-GM2: characterization of cell surface reactivity. (1986) (81)
Shared group-specific antigen of murine and feline leukemia viruses. (1968) (80)
Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. (1996) (79)
Characteristics of the structural components of the mouse mammary tumor virus. II. Viral proteins and antigens. (1971) (79)
A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity (1994) (78)
Dissecting cytotoxic T cell responses towards the NY‐ESO‐1 protein by peptide/MHC‐specific antibody fragments (2004) (78)
Overexpression of p53 Protein in Squamous Cell Carcinomas of Head and Neck Without Apparent Gene Mutations (1994) (78)
Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. (2007) (77)
A soluble antigen of the mammary tumor virus. (1967) (77)
Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. (2008) (77)
Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody. (2001) (76)
Biochemical analysis of two cell surface glycoprotein complexes, very common antigen 1 and very common antigen 2. Relationship to very late activation T cell antigens. (1987) (76)
Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity. (2008) (75)
Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity (2001) (75)
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. (2012) (74)
Somatic cell genetic analysis of human cell surface antigens: chromosomal assignments and regulation of expression in rodent-human hybrid cells. (1984) (74)
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. (2003) (74)
Expression of cancer-testis (CT) antigens in placenta. (2007) (73)
CT7 (MAGE‐C1) antigen expression in normal and neoplastic tissues (2002) (73)
Paraproteinemia and Reticulum Cell Sarcoma in an Inbred Mouse Strain (1966) (73)
Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses (2015) (73)
Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients (2006) (73)
Ly phenotype of cytotoxic T cells for syngeneic tumor (1976) (73)
Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters (2005) (73)
NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells (2009) (73)
Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. (2003) (73)
A phase I study of vaccination with NY‐ESO‐1f peptide mixed with Picibanil OK‐432 and Montanide ISA‐51 in patients with cancers expressing the NY‐ESO‐1 antigen (2011) (72)
Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma (1991) (72)
The gene for fibroblast activation protein alpha (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. (1995) (72)
Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity (2012) (72)
Group-specific viral antigens in the milk and tissues of mice naturally infected with mammary tumor virus or Gross leukemia virus. (1968) (71)
The antitumor monoclonal antibody 806 recognizes a high‐mannose form of the EGF receptor that reaches the cell surface when cells over‐express the receptor (2005) (71)
Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma (2005) (71)
Cancer vaccines: an overview. (2008) (70)
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium (2009) (70)
Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1 (2004) (70)
Real-Time, label-free monitoring of tumor antigen and serum antibody interactions. (2004) (70)
T311--an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. (2000) (69)
A33 antigen displays persistent surface expression (2008) (69)
Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. (1997) (69)
Immunoanatomic distribution of blood group antigens in the human urinary tract. Influence of secretor status. (1986) (69)
A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen (2007) (69)
Preparation of lymphocyte-specific antibody from anti-lymphocyte serum. (1968) (68)
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond (2010) (68)
Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients (2010) (68)
Cerebellar degeneration-related antigen: a highly conserved neuroectodermal marker mapped to chromosomes X in human and mouse. (1990) (68)
NY-ESO-1 Expression and Immunogenicity in Esophageal Cancer (2004) (68)
Purification and characterization of a human tumor necrosis factor from the LuKII cell line. (1985) (68)
AU cell-surface antigen of human malignant melanoma: solubilization and partial characterization. (1979) (68)
The Spontaneous CD8+ T-Cell Response to HLA-A2-Restricted NY-ESO-1b Peptide in Hepatocellular Carcinoma Patients (2004) (68)
G(AKSL2): a new cell surface antigen of the mouse related to the dualtropic mink cell focus-inducing class of murine leukemia virus detected by naturally occurring antibody (1979) (67)
Immunohistologic expression of blood‐group antigens in normal human gastrointestinal tract and colonic carcinoma (1986) (67)
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. (1980) (66)
Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody (1984) (66)
Changes in cell surface glycoprotein expression during differentiation of human keratinocytes. (1987) (66)
5'-structural analysis of genes encoding polymorphic antigens of chemically induced tumors. (1987) (66)
Antibodies specifically targeting a locally misfolded region of tumor associated EGFR (2009) (66)
SERUM-MEDIATED LEUKEMIA CELL DESTRUCTION IN AKR MICE (1973) (66)
Immunogenetics of human cell surface differentiation. (1989) (65)
Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs 1 (2003) (65)
Antibody response against NY‐ESO‐1 in CHP‐NY‐ESO‐1 vaccinated patients (2007) (65)
Immunoanatomic dissection of the human urinary tract by monoclonal antibodies. (1984) (65)
Interleukin 2-mediated Conversion of Ovarian Cancer-associated CD4+ Regulatory T Cells Into Proinflammatory Interleukin 17-producing Helper T Cells (2009) (64)
Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. (2000) (64)
Human sarcomas in culture. Foci of altered cells and a common antigen; induction of foci and antigen in human fibroblast cultures by filtrates. (1971) (64)
Immunotherapy for cancer. (1996) (64)
Biochemical and serological characteristics of natural 9-O-acetyl GD3 from human melanoma and bovine buttermilk and chemically O-acetylated GD3. (1990) (64)
Purification, characterization, and antitumor activity of nonrecombinant mouse tumor necrosis factor. (1986) (63)
Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells (1985) (63)
Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. (1987) (63)
ML: A New Antigen Found in Leukæmias and Mammary Tumours of the Mouse (1964) (63)
Definition of a unique cell surface antigen of mouse leukemia RL male 1 by cell-mediated cytotoxicity. (1979) (62)
Mouse monoclonal antibodies to human epithelial differentiation antigens expressed on the surface of ovarian carcinoma ascites cells. (1987) (62)
Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein (2013) (62)
A proteomic analysis of the Pichia pastoris secretome in methanol-induced cultures (2011) (62)
Factors affecting endotoxin removal from recombinant therapeutic proteins by anion exchange chromatography. (2009) (62)
ISOANTIGENS OF THE H-2 AND Tla LOCI OF THE MOUSE (1968) (62)
FORMATION OF CYTOXIC ANTIBODY AGAINST LEUKEMIAS INDUCED BY FRIEND VIRUS. (1963) (61)
Structural analysis of TL genes of the mouse. (1985) (61)
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies. (1984) (61)
Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. (1993) (61)
Identification of Breast Cancer-Restricted Antigens by Antibody Screening of SKBR3 cDNA Library Using a Preselected Patient's Serum (2002) (61)
Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas. (1989) (60)
In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. (2000) (60)
Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens. (1986) (60)
Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. (2003) (60)
Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. (2002) (60)
Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide Vaccination1 (2006) (60)
A REPORT ON SOME OBSERVATIONS WITH A SIMPLIFIED CYTOTOXIC TEST (1962) (60)
Genetic origin of tumor antigens. (1968) (60)
Alloantigen-induced T-cell proliferation: Lyt phenotype of responding cells and blocking of proliferation by Lyt antisera. (1980) (59)
Purification and Characterization of a Novel Restricted Antigen Expressed by Normal and Transformed Human Colonic Epithelium* (1996) (59)
Cancer is a somatic cell pregnancy. (2007) (59)
Cancer/testis antigen CT45: Analysis of mRNA and protein expression in human cancer (2009) (58)
Expression of tag‐72 in normal colon, transitional mucosa, and colon cancer (1989) (58)
Cell surface antigens of human bladder tumors: definition of tumor subsets by monoclonal antibodies and correlation with growth characteristics. (1986) (58)
Effects of dialyzable transfer factor in patients with breast cancer. (1974) (57)
Immunogenic properties of reticulum cell sarcomas of SJL/J mice. (1970) (57)
Cancer-testis (CT) antigen expression in medulloblastoma. (2008) (57)
Deep depletion of abundant serum proteins reveals low‐abundant proteins as potential biomarkers for human ovarian cancer (2009) (57)
A fetal antigen associated with human neoplasia. (1972) (57)
Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs. (2008) (57)
Human tumor immunology. (1971) (57)
p53 transformation-related protein: detection of an associated phosphotransferase activity. (1981) (57)
Another chapter in the long history of endotoxin (1987) (56)
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. (2007) (56)
Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancer. (2004) (56)
NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. (2003) (56)
Wild-type Gross leukemia virus. I. Soluble antigen (GSA) in the plasma and tissues of infected mice. (1968) (55)
THE PHAGOCYTOSIS OF TUMOR CELLS: IN VITRO (1964) (55)
Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). (2006) (55)
Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium. (1997) (54)
Effector mechanisms of the anti-cancer immune responses of macrophages in SR/CR mice. (2006) (54)
Loss of skin allograft tolerance by chimeras. (1968) (54)
LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. (2007) (54)
MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer (2011) (54)
A Study of Passive Immunization Against a Transplanted G+ Leukemia with Specific Antiserum.∗ (1967) (54)
Mouse Leukæmias: Genetic Determination of the TL (Thymus–leukæmia) Antigen in the Mouse (1964) (54)
Production of immunoglobulins and their subunits by human tissue culture cell lines. (1967) (54)
Cell Surface Antigens: Serial Sectioning of Single Cells as an Approach to Topographical Analysis (1971) (53)
124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET (2011) (53)
Cell‐mediated cytotoxicity for cultured autologous melanoma cells (1979) (53)
Modulation of TL (thymus-leukemia) antigens by Fab-fragments of TL antibody. (1968) (53)
Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF (2008) (53)
NY‐CO‐58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer (2010) (52)
Protein p53 and inducer-mediated erythroleukemia cell commitment to terminal cell division. (1983) (52)
Immunofluorescent monoclonal antibody detection of breast cancer in bone marrow: sensitivity in a model system. (1989) (52)
MAGE-A3 is highly expressed in a subset of colorectal cancer patients. (2012) (51)
Cancer/testis (CT) antigens are expressed in fetal ovary. (2007) (51)
Cell surface glycoproteins of human tumor cell lines: unusual characteristics of malignant melanoma. (1979) (51)
Antigenic Conversion of Established Leukæmias by an Unrelated Leukæmogenic Virus (1964) (51)
Analysis of the expression of N-glycolylneuraminic acid-containing gangliosides in cells and tissues using two human monoclonal antibodies. (1988) (51)
IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. (2005) (50)
Autoantibodies against cancer antigens. (2009) (50)
Monoclonal antibodies to three widely distributed human cell surface antigens. (1983) (50)
Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients. (2003) (50)
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™ (2011) (49)
Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. (1995) (49)
Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). (1997) (49)
Detection of antibody to autologous human leukemia cells by immune adherence assays. (1977) (49)
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. (2010) (48)
Serological identification of breast cancer‐related antigens from a Saccharomyces cerevisiae surface display library (2005) (48)
A novel method to localize antibody-targeted cancer deposits intraoperatively using handheld PET beta and gamma probes (2008) (48)
Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. (2007) (48)
Immunoreactivity with the Anti-MAGE Antibody 57B in Malignant Melanoma: Frequency of Expression and Correlation with Prognostic Parameters (2000) (48)
Analysis of peripheral and local anti‐tumor immune response in esophageal cancer patients after NY‐ESO‐1 protein vaccination (2008) (48)
Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. (2009) (48)
Cell surface antigens of human trophoblast and choriocarcinoma defined by monoclonal antibodies (1985) (47)
Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells (1983) (47)
Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250 (2011) (47)
Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. (2008) (47)
Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. (2005) (46)
Leukæmia-inhibiting Properties and L-Asparaginase Activity of Sera from Certain South American Rodents (1963) (46)
Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts. (2001) (46)
Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma. (2011) (46)
Abelson antigen: a viral tumor antigen that is also a differentiation antigen of BALB/c mice. (1978) (46)
Immunohistologic dissection of the human kidney using monoclonal antibodies. (1985) (46)
Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient. (1990) (46)
Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model. (2001) (45)
Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas (1999) (45)
Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. (2012) (45)
Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. (2003) (45)
New Visual Markers of Antibody for Electron Microscopy (1969) (45)
Analysis of human ovarian tumor antigens using heterologous antisera: Detection of new antigenic systems (1978) (45)
Trypanosoma cruzi as an effective cancer antigen delivery vector (2011) (45)
Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR (2005) (45)
Striking Immunodominance Hierarchy of Naturally Occurring CD8+ and CD4+ T Cell Responses to Tumor Antigen NY-ESO-11 (2006) (44)
Distribution of the ganglioside GD3 in the human nervous system detected by R24 mouse monoclonal antibody (1984) (44)
Peptide Vaccine Induces Enhanced Tumor Growth Associated with Apoptosis Induction in CD8+ T Cells (2010) (44)
Nonclassical Antigen-Processing Pathways Are Required for MHC Class II–Restricted Direct Tumor Recognition by NY-ESO-1–Specific CD4+ T Cells (2013) (44)
Specific antigens of tumors and leukemias of experimental animals. (1966) (44)
Effect of recombinant tumor necrosis factor on HL‐60 cells: Cell‐cycle specificity and synergism with actinomycin D (1987) (44)
Human melanoma proteoglycan: expression in hybrids controlled by intrinsic and extrinsic signals. (1986) (43)
In vitro Stimulation of CD8 and CD4 T Cells by Dendritic Cells Loaded with a Complex of Cholesterol-Bearing Hydrophobized Pullulan and NY-ESO-1 Protein: Identification of a New HLA-DR15–Binding CD4 T-Cell Epitope (2006) (43)
OCCURRENCE OF SOLUBLE ANTIGEN IN THE PLASMA OF MICE WITH VIRUS-INDUCED LEUKEMIA. (1964) (43)
Isoforms of the human PDZ-73 protein exhibit differential tissue expression. (1999) (43)
Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. (2010) (43)
Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2. (2006) (43)
Preferential Nuclear and Cytoplasmic NY-BR-1 Protein Expression in Primary Breast Cancer and Lymph Node Metastases (2006) (42)
Analysis of the antibody response to immunization with purified O‐acetyl GD3 gangliosides in patients with malignant melanoma (1995) (42)
Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX. (2011) (42)
Characterization of a cDNA encoding a 34-kDa Purkinje neuron protein recognized by sera from patients with paraneoplastic cerebellar degeneration. (1989) (42)
Assignment of the gene for the beta subunit of thyroid-stimulating hormone to the short arm of human chromosome 1. (1986) (42)
Opsonization of Cells by Isoantibody in vitro (1963) (41)
Thymus-leukemia (TL) antigens of the mouse. Analysis of TL mRNA and TL cDNA TL+ and TL- strains (1985) (41)
Inhibitory Effect of Guinea Pig Serum on a Number of New Leukæmias in Mice (1963) (41)
Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse (2008) (41)
Immunization With a Recombinant MAGE-A3 Protein After High-dose Therapy for Myeloma (2007) (41)
Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. (2004) (40)
Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient (2008) (40)
Identification of a new cancer/testis gene family, CT47, among expressed multicopy genes on the human X chromosome (2006) (40)
Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas (2010) (40)
Induction and immunological properties of tumor necrosis factor. (1978) (40)
SOME BIOCHEMICAL PROPERTIES OF THYMUS LEUKEMIA ANTIGENS SOLUBILIZED FROM CELL MEMBRANES BY PAPAIN DIGESTION (1973) (40)
Monoclonal antibody to an intracellular antigen images human melanoma transplants in nu/nu mice. (1987) (40)
Histoincompatibility attributable to genes near H-2 that are not revealed by hemagglutination or cytotoxicity tests. (1972) (40)
Two human monoclonal antibodies reacting with the major gangliosides of human melanomas and comparison with corresponding mouse monoclonal antibodies. (1989) (39)
Endotoxin-induced tumor necrosis factor. (1980) (39)
OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. (2006) (39)
Monoclonal antibodies against Galα 1 −4Galß 1 −4Glc(Pk, CD77) produced with a synthetic glycoconjugate as immunogen: Reactivity with carbohydrates, with fresh frozen human tissues and hematopoietic tumors (1991) (39)
IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. (2004) (39)
Extracellular matrix-modulated expression of human cell surface glycoproteins A42 and J143. Intrinsic and extrinsic signals determine antigenic phenotype (1986) (39)
Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. (2002) (39)
The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines (1985) (39)
An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. (2004) (39)
Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. (2001) (39)
TL antigen as a transplantation antigen recognized by TL-restricted cytotoxic T cells (1994) (38)
Chromosome assignment of the tumor-specific antigen of a 3- methylcholanthrene-induced mouse sarcoma (1981) (38)
Mouse monoclonal IgM antibody against human lung cancer line SK-LC-3 with specificity for H(O) blood group antigen. (1982) (38)
Tla-region genes and their products (1987) (38)
Mouse Lyt-2 antigen: evidence for two heterodimers with a common subunit. (1982) (37)
A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. (2005) (37)
Targeted therapy of renal cell carcinoma: Synergistic activity of cG250‐TNF and IFNg (2009) (37)
Characterization of two newly established human cell lines from patients with large‐cell anaplastic lung carcinoma (1982) (37)
DEMONSTRATION OF DELAYED HYPERSENSITIVITY TO SOLUBLE ANTIGENS OF CHEMICALLY INDUCED TUMORS BY INHIBITION OF MACROPHAGE MIGRATION (1969) (37)
Accelerated Rejection of Male Skin Isografts by Female G57BL Mice Infected with Bacillus Calmette-Guérin (B.C.G.).∗ (1962) (37)
NY-BR-1 is a Differentiation Antigen of the Mammary Gland (2007) (36)
A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. (2007) (36)
Immunotherapeutic strategies for high-risk bladder cancer. (2007) (36)
Heteroclitic serological response in esophageal and prostate cancer patients after NY‐ESO‐1 protein vaccination (2012) (35)
A unique antigenic epitope of human melanoma is carried on the common melanoma glycoprotein gp95/p97 (1989) (35)
Characterization of Preexisting MAGE-A3-Specific CD4+ T Cells in Cancer Patients and Healthy Individuals and Their Activation by Protein Vaccination1 (2009) (35)
Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM). (1996) (35)
Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4+ T Cells (2006) (35)
NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. (2013) (35)
Wild-type Gross leukemia virus. II. Influence of immunogenetic factors on natural transmission and on the consequences of infection. (1968) (35)
A common transformation-related protein in murine sarcomas and leukemias. (1980) (35)
Antibody response to immunization with purified GD3 ganglioside and GD3 derivatives (lactones, amide and gangliosidol) in the mouse. (1990) (34)
Serum containing endotoxin-induced tumour necrosis factor substitutes for helper T cells (1976) (34)
Class 1 (unique) tumor antigens of human melanoma: identification of unique and common epitopes on a 90-kDa glycoprotein. (1988) (34)
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. (2009) (34)
Location of the Second Gene Required for Expression of the Leukemia-Associated Mouse Antigen GIX (1972) (34)
Tumor necrosis factor and IFN induce a common set of proteins. (1988) (33)
Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. (2008) (33)
Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. (2004) (33)
Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels (2007) (33)
Preleukemic expression of TL antigens in x-irradiated C57BL/6 mice (1977) (33)
Directed evolution for improved secretion of cancer-testis antigen NY-ESO-1 from yeast. (2006) (33)
Recognition of galactosylgloboside by monoclonal antibodies derived from patients with primary lung cancer. (1988) (33)
Heat Shock Protein 90-Mediated Peptide-Selective Presentation of Cytosolic Tumor Antigen for Direct Recognition of Tumors by CD4+ T Cells (2012) (33)
Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model. (2003) (32)
A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. (2004) (32)
Serological analysis of BALB/C methylcholanthrene sarcoma Meth A by SEREX: Identification of a cancer/testis antigen (2000) (32)
The antigen identified by a mouse monoclonal antibody raised against human renal cancer cells is the adenosine deaminase binding protein. (1984) (31)
Murine-leukemia-virus-related cell-surface antigens as serological markers of AKR ecotropic, xenotropic, and dualtropic viruses. (1980) (31)
Role of human chromosome 11 in determining surface antigenic phenotype of normal and malignant cells. Somatic cell genetic analysis of eight antigens, including putative human Thy-1 (1985) (31)
Expression and immunogenicity of NY‐ESO‐1 in hepatocellular carcinoma (2006) (30)
Trisomy of chromosome 15 in x-ray induced mouse leukemia. Abstr. (1977) (30)
Ex-Vivo Analysis of CD8+ T Cells Infiltrating Colorectal Tumors Identifies a Major Effector-Memory Subset with Low Perforin Content (2006) (30)
Genes controlling gp25/30 cell-surface molecules map to chromosomes X and Y and escape X-inactivation. (1985) (30)
Glycoprotein A34, a novel target for antibody-based cancer immunotherapy. (2006) (29)
Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells (1982) (29)
SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. (2004) (29)
Spontaneous antibody, and CD4 and CD8 T‐cell responses against XAGE‐1b (GAGED2a) in non‐small cell lung cancer patients (2012) (29)
Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice. (1998) (29)
Short communication: A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy (2003) (28)
Gure, A. O. et al. CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis. Int. J. Cancer 85, 726-732 (2000) (28)
G(RADA1): a new cell surface antigen of mouse leukemia defined by naturally occurring antibody and its relationship to murine leukemia virus (1978) (28)
Jungbluth AA, Chen Y‐T, Stockert E., Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ. Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues. International Journal of Cancer 2001; 92(6) 856–860. (2002) (28)
SSX antigens as tumor vaccine targets in human sarcoma. (2003) (28)
Thymus Cells of Radiation-Chimeras: TL Phenotype, Sensitivity to Guinea-Pig Serum, and Origin from Donor Cells (1965) (28)
Tumor‐reactive CD8+ T‐cell clones in patients after NY‐ESO‐1 peptide vaccination (2007) (28)
A phase I trial of humanized monoclonal antibody huA33 in patients with early gastric cancer: Imaging studies, biodistribution, pharmacokinetics, immunohistochemistry, and quantitative tumor uptake. (2004) (27)
Tolerance of Sk-incompatibte Skin Grafts (1973) (27)
SEREX analysis of gastric cancer antigens (2000) (27)
E Antigen: A Cell-Surface Antigen of C57BL Leukemias (1970) (27)
TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49. (1995) (27)
negatively regulated by LAG-3 and PD-1 in human ovarian cancer (2010) (27)
GENETIC DETERMINATION OF THE TL (THYMUSLEUKAEMIA) ANTIGEN IN THE MOUSE. (1964) (27)
Immuno-PET Quantitation of de2-7 Epidermal Growth Factor Receptor Expression in Glioma Using 124I-IMP-R4–Labeled Antibody ch806 (2010) (27)
Immunopathologic analysis of a panel of mouse monoclonal antibodies reacting with human ovarian carcinomas and other human tumors. (1985) (26)
MOUSE ISOANTIGENS: SEPARATION OF SOLUBLE TL (THYMUS-LEUKEMIA) ANTIGEN FROM SOLUBLE H-2 HISTOCOMPATIBILITY ANTIGEN BY COLUMN CHROMATOGRAPHY (1967) (26)
Frequent MAGE Mutations in Human Melanoma (2010) (26)
Vaccination With a Recombinant Protein Encoding the Tumor-specific Antigen NY-ESO-1 Elicits an A2/157-165-specific CTL Repertoire Structurally Distinct and of Reduced Tumor Reactivity Than That Elicited by Spontaneous Immune Responses to NY-ESO-1-expressing Tumors (2009) (26)
Wild-type Gross leukemia virus. 3. Serological tests as indicators of leukemia risk. (1968) (26)
Expression of TL, H-2, and chimeric H-2/TL genes in transgenic mice: abnormal thymic differentiation and T-cell lymphomas in a TL transgenic strain. (1989) (26)
A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved. (2002) (26)
Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study. (2010) (26)
Structure-Activity Profiles of Ab-Derived TNF Fusion Proteins1 (2006) (26)
Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. (2005) (26)
Induction of antibodies reactive with GM2 ganglioside after immunization with lipopolysaccharides from Campylobacter jejuni (1996) (26)
A molecular mechanism of complement resistance of human melanoma cells. (1986) (26)
Cell surface molecules of human melanoma. Immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigenic systems. (1989) (26)
The humoral immune response to head and neck cancer antigens as defined by the serological analysis of tumor antigens by recombinant cDNA expression cloning. (2004) (26)
Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1 (2008) (25)
A comment on the genetic data relating to expression of TL antigens. (1971) (25)
A transformation-associated 130-kD cell surface glycoprotein is growth controlled in normal human cells (1988) (25)
Identification of cancer antigens in breast cancer by the SEREX expression cloning method (1999) (25)
Monoclonal antibody-based therapy for renal cell carcinoma. (2003) (25)
Direct immobilization of gangliosides onto gold-carboxymethyldextran sensor surfaces by hydrophobic interaction: applications to antibody characterization. (1998) (25)
A new differentiation antigen of plasma cells (1971) (25)
Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients (2006) (25)
Electrophoretic analysis of the novel antigen for the gastrointestinal‐specific monoclonal antibody, A33 (1997) (25)
Assignment of human nerve growth factor receptor gene to chromosome 17 and regulation of receptor expression in somatic cell hybrids (1986) (25)
Vaccination with Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR52b-restricted CD4+ T Cell Responses with a Conserved T Cell Receptor Repertoire (2009) (25)
Identification and characterization of mouse SSX genes: a multigene family on the X chromosome with restricted cancer/testis expression. (2003) (24)
Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals. (2005) (24)
Efficient Synthesis of Ganglioside GM2 for Use in Cancer Vaccines (1997) (24)
Demonstration of delayed hypersensitivity to soluble antigens of chemically induced tumors by inhibition of macrophage migration. (1970) (24)
Structural comparisons of TL antigens derived from normal and leukemia cells of Tl+ and TL- strains and relationship to genetically linked H-2 major histocompatibility complex products. (1981) (24)
MAGE antigen expression in monophasic and biphasic synovial sarcoma. (2002) (23)
Influence of 5' flanking sequences on TL and H-2 expression in transfected L cells. (1988) (23)
Cytotoxic reactions of murine lymphoid cells studied with a tritiated proline microcytotoxicity test. (1975) (23)
A phase I clinical trial with monoclonal antibody ch 806 targeting transitional state and mutant epidermal growth factor receptors (2007) (23)
Immunohistochemical and Reverse Transcription-Polymerase Chain Reaction Expression Analysis of Tyrosinase and Microphthalmia-Associated Transcription Factor in Angiomyolipomas (2001) (23)
RELATION OF CHROMOSOME 4 (LINKAGE GROUP VIII) TO MURINE LEUKEMIA VIRUS-ASSOCIATED ANTIGENS OF AKR MICE (1973) (23)
Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles. (2006) (23)
Regulation of IFN‐γ production in granulocyte‐macrophage colony‐stimulating factor‐deficient mice (1998) (23)
Biochemical analysis of a 130,000 molecular weight glycoprotein on human melanoma cells. (1983) (23)
A human monoclonal autoantibody to breast cancer identifies the PDZ domain containing protein GIPC1 as a novel breast cancer-associated antigen (2008) (23)
Identification of a high molecular weight endothelial cell surface glycoprotein, endoGlyx-1, in normal and tumor blood vessels. (1994) (23)
Contact Reactivity to Carcinogenic Polycyclic Hydrocarbons (1963) (23)
Pharmacokinetics and microdistribution of polyethylene glycol‐modified humanized A33 antibody targeting colon cancer xenografts (2000) (23)
Identification of an SSX-2 Epitope Presented by Dendritic Cells to Circulating Autologous CD4+ T Cells1 (2004) (22)
ANTIGENIC STRUCTURE OF CELL SURFACES (1969) (22)
The relation of linkage group ix to leukemogenesis in the mouse, p. 171-185. In p. Emmelot & p. Bentvelzen, [eds.], Rna viruses and the host genome in oncogenesis. Amsterdam, north holland publ. (1972) (22)
Relation of cell surface antigens on methylcholanthrene-induced fibrosarcomas to immunoglobulin heavy chain complex variable region-linked T cell interaction molecules. (1983) (22)
Cancer vaccines 2003: opening address. (2003) (22)
Expression of cancer testis (CT) antigens in ovary (2004) (22)
Endotoxin-induced serum factor controlling differentiation of bone-marrow-derived lymphocytes. (1977) (22)
Reduction of x-ray lethality in mice by agents affecting the reticuloendothelial system. (1961) (22)
Tolerance of Sk-incompatible skin grafts. (1973) (22)
Rebmab200, a Humanized Monoclonal Antibody Targeting the Sodium Phosphate Transporter NaPi2b Displays Strong Immune Mediated Cytotoxicity against Cancer: A Novel Reagent for Targeted Antibody Therapy of Cancer (2013) (21)
A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. (2013) (21)
HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma (2005) (21)
Cancer immunology. What is the status of the possibility of attacking cancer cells by means of their " foreign " labels? (1977) (21)
Neutral glycosphingolipid expression in B‐cell neoplasms (1991) (21)
The soluble antigens of BALB/c sarcoma Meth-A: a relationship between a serologically defined tumor-specific surface antigen (TSSA) and the tumor-associated transplantation antigen (TATA). (1981) (21)
HLA Class I–Associated Immunodominance Affects CTL Responsiveness to an ESO Recombinant Protein Tumor Antigen Vaccine (2009) (20)
Estimation of ABO(H) isoantigen expression in bladder tumors. (1985) (20)
Serological identification of hamster oncornaviruses. (1971) (20)
Definition of an antigenic system associated with Burkitt's lymphoma. (1967) (20)
Rejection of skin allografts by radiation chimaeras: selective gene action in the specification of cell surface structure. (1970) (20)
Diagnosis of renal proximal tubular injury by urinary immunoassay for a proximal tubular antigen, the adenosine deaminase binding protein. (1987) (20)
Immunological Enhancement of a Leukæmia (1962) (20)
Development of monoclonal antibodies specific for the human sodium-dependent phosphate co-transporter NaPi2b. (2008) (20)
CD4+ T Cell Responses to SSX-4 in Melanoma Patients1 (2005) (20)
Analysis of human monoclonal antibodies derived from lymphocytes of patients with cancer. (1984) (20)
Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2. (2005) (20)
Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells. (1980) (19)
Linkage groups of the theta and Ly-A loci. (1971) (19)
A cell surface antigen of the mouse related to xenotropic MuLv defined by naturally occurring antibody and monoclonal antibody. Relation to Gix G(rada1), G(aksl2) systems of MuLV-related antigens (1981) (19)
Micro-sequencing strategies for the human A33 antigen, a novel surface glycoprotein of human gastrointestinal epithelium. (1998) (19)
Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen. (2007) (19)
Spontaneous release of cytotoxic alloantibody from viable cells sensitized in excess antibody. (1971) (19)
Response to 'A cancer immunosurveillance controversy' (2004) (18)
Soluble TL and H-2 antigens prepared from a TL positive leukaemia of a TL negative mouse strain. (1969) (18)
Novel Mechanistic Insights into Arginine Deiminase Pharmacology Suggest 18F-FDG Is Not Suitable to Evaluate Clinical Response in Melanoma (2012) (18)
Human Cancer Immunology (1980) (18)
Tumor infiltrating lymphocytes: indicators of tumor-related immune responses. (2007) (18)
Two cell-surface markers for human chromosome 1 in interspecies hybrids (1984) (18)
Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871. (2002) (18)
Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses. (2005) (18)
SUPPRESSION OF MURINE LEUKEMIAS BY L-ASPARAGINASE (1967) (18)
PRODUCTION OF TL ANTIBODY BY MICE IMMUNIZED WITH TL- CELL POPULATIONS (1973) (17)
Effect of intravesical Bacillus Calmette-Guérin on detection of a urothelial differentiation antigen in exfoliated cells of carcinoma in situ of the human urinary bladder. (1985) (17)
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma (2020) (17)
The technique of obtaining thymocytes from living mice. (1971) (17)
Physical and genetic mapping of the CDR gene with particular reference to its position with respect to the FRAXA site. (1991) (17)
In vitro detection of occult bone marrow metastases in patients with colorectal cancer hepatic metastases (1998) (16)
L-asparagine and leukemia. (1968) (16)
p53 content in relation to cell growth and proliferation in murine L1210 leukemia and normal lymphocytes. (1986) (16)
Inducing Efficient Cross-priming Using Antigen-coated Yeast Particles (2008) (16)
L-asparaginase in the treatment of neoplastic diseases of the dog, cat and cow. (1970) (16)
Current enigmas in cancer research. (1973) (16)
Assessment of Vaccine-Induced CD4 T Cell Responses to the 119-143 Immunodominant Region of the Tumor-Specific Antigen NY-ESO-1 Using DRB1*0101 Tetramers (2010) (16)
Inhibition of AKR leukemogenesis by SMX-1, a dualtropic murine leukemia virus. (1980) (16)
Differential expression of the human Thy-1 gene in rodent-human somatic cell hybrids [corrected]. (1987) (16)
Localisation on human chromosome 19 of three genes for cell surface antigens defined by monoclonal antibodies. (1987) (15)
Monoclonal antibody MX 35 detects the membrane transporter NaPi 2 b ( SLC 34 A 2 ) in human carcinomas (2005) (15)
Identification of Tumor-Associated Antigens from Medullary Breast Carcinoma by a Modified SEREX Approach (2010) (15)
Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine. (2004) (15)
Cat interferon inhibits feline leukaemia virus infection in cell culture. (1972) (15)
A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients. (2006) (15)
Serological identification of antigens associated with renal cell carcinoma. (2002) (15)
Identification of a human homologue of the murine tumor rejection antigen GP96. (1989) (15)
DNA-mediated transfer of human melanoma cell surface glycoprotein gp130: identification of transfectants by erythrocyte rosetting (1985) (15)
Three mouse monoclonal antibodies to human differentiation antigens: reactivity with two mucin-like antigens and with connective tissue fibers. (1985) (15)
Abstract #2593: Bioinformatics construction of the human surfaceome and experimental identification of new tumor targets at cell surface (2009) (14)
Split T Cell Tolerance against a Self/Tumor Antigen: Spontaneous CD4+ but Not CD8+ T Cell Responses against p53 in Cancer Patients and Healthy Donors (2011) (14)
A Comparison of Concurrent and Delayed Tests for Antitumor Activity of L-Asparaginase.∗ (1967) (14)
Tumor-specific Crosslinking of GITR as Costimulation for Immunotherapy (2010) (14)
Serological analysis of leukemia antigens of the mouse. (1966) (14)
Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma. (2013) (14)
HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones. (2004) (14)
Immunohistochemical characterization of two monoclonal antibodies, P25.48 and P25.91, which define a new prostate-specific antigen. (1988) (14)
Quantitative real-time RT-PCR analysis of NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and tumors, and correlation of the protein expression with the mRNA copy number. (2005) (13)
Five novel cell surface antigens of CNS neoplasms (1989) (13)
A serological study of polyhedral cytoplasmic viruses isolated from amphibia. (1968) (13)
Monitoring CD 8 T cell responses to NY-ESO-1 : correlation of humoral and cellular immune responses (2017) (13)
Expression and purification of cGMP grade NY‐ESO‐1 for clinical trials (2011) (13)
Phase I Trial of 131 I-huA 33 in Patientswith Advanced Colorectal Carcinoma (2005) (13)
A novel heteromorphic human cell surface alloantigen, gp60, defined by a human monoclonal antibody. (1989) (12)
PIasma-Mediated Leukemia Cell Destruction: Concentration and Purification of the Antileukemia Factor 1 (1977) (12)
TYPING OF MOUSE LEUKAEMIAS BY SEROLOGICAL METHODS. (1964) (12)
Cell surface antigens of murine leukemias induced by radiation leukemia virus. Recognition of individually distinct cell surface antigens by cytotoxic T cells on leukemias expressing crossreactive transplantation antigens (1986) (12)
KP-CoT-23 (CCDC83) is a novel immunogenic cancer/testis antigen in colon cancer. (2012) (12)
Another visual marker of antibody for electron microscopy. (1971) (12)
SurfaceomeDB: a cancer-orientated database for genes encoding cell surface proteins. (2012) (12)
Overcoming regulatory T‐cell suppression by a lyophilized preparation of Streptococcus pyogenes (2013) (12)
The immunogenetics of differentiation in the mouse. (1978) (12)
Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients. (1998) (12)
Chromosomal Lesion associated with Carcinogen-induced Tumours in Mice (1961) (12)
Tumor Necrosis Factor1 (1990) (12)
Identification of new NY‐ESO‐1 epitopes recognized by CD4+ T cells and presented by HLA‐DQ B1 03011 (2006) (12)
PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer (2015) (12)
Signaling and signaling dysfunction through the interferon gamma receptor. (1998) (12)
The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants. (1985) (12)
Expression and purification of the cancer antigen SSX2: a potential cancer vaccine. (2007) (12)
Definition of an extracellular matrix protein in rostral portions of the human central nervous system (1988) (11)
DNA-mediated gene transfer of a human cell surface 170-kilodalton glycoprotein. Evidence for association with an endogenous murine protein. (1987) (11)
Cancer Immunology: The Search for Specificityâ€”G. (2006) (11)
Possible role of a retrovirus in the expression of tumor‐specific antigens of the meth a sarcoma. (1982) (11)
Urine antibody against human cancer antigen NY-ESO-1. (2002) (10)
Cancer Vaccine Collaborative 2002: opening address. (2003) (10)
Class 1 (unique) tumor antigens of human melanoma: partial purification and characterization of the FD antigen and analysis of a mouse polyclonal antiserum. (1987) (10)
Expression of the human cancer/testis antigen NY-SAR-35 is activated by CpG island hypomethylation (2011) (10)
The Human Cell Surfaceome of Breast Tumors (2013) (10)
Prospects for immunotherapy of human cancer. (1968) (10)
Cell surface antigen of human neuroblastomas is related to nuclear antigen of normal cells. (1985) (10)
Antitumor Activity of Microbial Products and Tumor Necrosis Factor (1988) (10)
Inhibition of HeLa cell cultures by preparations of Escherichia coli L-asparaginase. (1968) (10)
A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation (2012) (9)
High-level expression of a phage display-derived scFv in Pichia pastoris. (2009) (9)
A comparative study of the antitumor effectiveness of E. coli and Erwinia asparaginases. (1976) (9)
ANTIGENIC MODULATION (1982) (9)
Serological studies of the feline leukemia virus. (1970) (9)
Synthesis of a Structurally Defined Antigen–Immunostimulant Combination for Use in Cancer Vaccines (1999) (9)
Pillars Article: IFNγ and Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity. Nature. 2001. 410: 1107-1111. (2018) (9)
Phase I trial of hu3S193 in patients with advanced epithelial cancers which express the Lewis-y antigen. (2004) (8)
Comparison of the immunogenicity of Montanide ISA 51 adjuvant and cytokine-matured dendritic cells in a randomized controlled clinical trial of melanoma vaccines. (2009) (8)
Serolgic analysis of human cancer (1990) (8)
Labelling of mouse alloantibody with tritiated dl-alanine. (1969) (8)
Cell surface antigens of chemically induced sarcomas of inbred mice. (1980) (8)
Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8. (2009) (8)
Monoclonal antibody therapy of kidney cancer. (2003) (8)
Implications of TL phenotype changes in an H-2-loss variant of a transplanted H-2b-H-2a leukemia. (1970) (8)
Specifi ' city analysis of blood group Lewis-y ( Ley ) antibodies generated against synthetic and natural Ley determinants ( anti-LeY antibody / humanized antibody / synthetic neoglycoprotein ) (2005) (8)
Cytotoxic Activity of Isoantibody on Sarcoma 1.∗ (1962) (8)
[Expression of multiple cancer-testis antigen genes in non-small cell lung cancer treated by chemotherapy prior surgery]. (2004) (8)
TREATMENT OF LYMPHOSARCOMA IN THE DOG WITH L-ASPARAGINASE (1967) (8)
Antigenic phenotypes of cultured malignant astrocytomas: Identification of lineage-consistent, lineage-independent and putative tumor-restricted antigenic expression (1989) (8)
Antibody therapy in renal cell carcinoma (2008) (8)
Immunotherapy of colon cancer: Prospects for developing immunogenic vaccines based on autologous serological typing (1980) (8)
MAGE-A 3 is highly expressed in a subset of colorectal cancer patients (2011) (8)
Correction: Frequent MAGE Mutations in Human Melanoma (2010) (7)
Three human cell surface antigen systems determined by genes on chromosome 12 (1984) (7)
Translation of cancer immunotherapies (2004) (7)
A Preliminary Report on the Serology of Lucké and Burkitt Herpes-type Viruses: A Shared Antigen (1969) (7)
Treatment of feline lymphosarcoma with feline blood constituents. (1976) (7)
Leukemia-inhibitory and l-asparaginase activities of guinea pig serum. Abstr. (1964) (7)
8000 Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: preliminary data from a phase-2 study (2009) (7)
HUMAN SARCOMAS IN CULTURE (1971) (7)
Chromosomal assignment of the gene encoding the mouse tumor rejection antigen gp96 (2004) (7)
Differential expression of the Thy-1 Gene in Rodent-Human Somatic Cell Hybrids (1987) (7)
Structural Basis for Tumor Cell Recognition by the Immune System (1989) (6)
Phase I/II study of arginine deiminase (ADI-PEG 20) in patients with advanced malignant melanoma (MM). (2016) (6)
Temporary plasma-induced remission of lymphoblastic leukemia in a dog. (1981) (6)
A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients (pts) with advanced renal cell carcinoma (RCC). (2004) (6)
Improved secretion of the cancer-testis antigen SSX2 in Pichia pastoris by deletion of its nuclear localization signal (2010) (6)
Effect of prior splenectomy on the growth of Sarcoma 180 in normal and Bacillus Calmette-Guérin infected mice (1962) (6)
Identification of phosphate transporter NaPi2b as MX35 cancer antigen by modified SEREX approach (2008) (5)
Reply to Coggin's letter (1989) (5)
Cell-surface antigens determined by human chromosomes 1 and 12: Comparative serological and somatic cell genetic analysis of eight antigenic systems (1986) (5)
Increased phagocytic activity of the res produced by transmissible agent derived from transplantable tumors. Abstr. (1961) (5)
Structural evidence that the small subunit found associated with the TL antigen is β2-microglobulin (2004) (4)
Feline leukemia virus: detection of group-specific viral antigen and infectious virus by a complement-fixation test. (1970) (4)
Ferritin-Conjugated Antibody for the Demonstration of Isoantigens on the Surface of Murine Cells (1968) (4)
Nature of focal lesion and location of skin stimulus influence pattern and distribution of somatosensory evoked potentials (SEP): Forensic and clinical uses (1979) (4)
Erratum: Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans (Proceedings of the National Academy of Sciences of the United States of America (July 20, 2004) 101, 29 (10697-10702)) (2005) (4)
Generation of monoclonal antibodies to cancer / testis ( CT ) antigen CT 10 / MAGE-C 2 (2005) (4)
Tumor-specific antigens. (1980) (4)
Analysis of a mouse monoclonal antibody detecting the H type 1 blood group determinant. (1988) (4)
Phase II study of ADI-PEG 20 in patients with relapsed sensitive or refractory small cell lung cancer. (2012) (3)
A first-in-human phase I study of MORAb-004 (MOR4), a humanized monoclonal antibody recognizing TEM-1 (endosialin), in patients with solid tumors. (2011) (3)
Cancer-testis (CT) antigen expression in (2008) (3)
Increased anti-leukaemia activity of E. coli asparaginase in mice infected with L.D.H.-elevating virus. (1968) (3)
Studies of Thoracic Duct Lymphocytes of Mice (1968) (3)
Vaccination with MAGE-3 Protein Can Induce a Potent Immune Response in a Healthy Donor Which Can Be Adoptively Transferred Via Stem Cell Transplant (Tx) to a Multiple Myeloma (MM) Patient. (2005) (3)
Tumor necrosis factor. Further studies. Abstr. (1975) (3)
CT7 (MAGE-C1)-Specific Cellular Immune Responses in the Bone Marrow Microenvironment of Multiple Myeloma Patients. (2005) (3)
A phase 1 clinical trial of NY-ESO-1 protein formulated with immunostimulatory complexes (ISCOM® adjuvant) in patients with minimal residual disease (2003) (3)
Functional relationships of Lyt-2 and Lyt-3 expression and T-cell cytotoxicity: a new model system. (1985) (3)
MAGE-A Inhibits Apoptosis In Proliferating Multiple Myeloma Cells (2010) (3)
Anti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab 100) in patients with advanced platinum resistant/refractory (PRR) ovarian cancer (OC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC). (2011) (3)
Current Status of the Search for Melanoma-Specific Antigens (1981) (3)
Reticuloendothelial function in various strains of mice. Abstr. (1960) (3)
The influence of cimetidine versus ranitidine on doxepin pharmacokinetics (2004) (2)
Antineoplastic and toxic effects of diets deficient in selected amino acids. Abstr. (1975) (2)
Booster vaccination of non-small cell lung cancer (NSCLC) patients with MAGEA3 protein and AS02B adjuvant (2007) (2)
Th 1 / Th 2 CD 4 + T cell responses against NY-ESO-1 in HLA-DPB 1 * 0401 / 0402 patients with epithelial ovarian cancer (2004) (2)
Immunization of ovarian cancer patients with an NY-ESO-1 peptide of dual MHC class I and II specificities plus incomplete Freund adjuvant induces simultaneous humoral, CD4+ and CD8+ T-cell responses (2005) (2)
Inhibition of the induction of contrasuppression by antisera against tumor-associated surface antigens on methylcholanthrene-induced sarcomas. (1983) (2)
Comprehensive analysis of T-cell responses after vaccination with NY-ESO-1 protein (2005) (2)
TPTE "Cancer/Testis" antigen is a candidate target for immunotherapy in epithelial ovarian carcinoma (2005) (2)
CD8+ tumor-infiltrating lymphocytes as a statistically significant marker of disease recurrence and survival in transitional cell carcinoma patients. (2006) (2)
LJ Old Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD 3 monoclonal antibody KM 871 (2002) (2)
In vivo inhibition of mouse leukemia by cytotoxic t-cell clones and exogenous il-2. Abstr. (1982) (2)
Immunological enhancement of a leukaemia. (1962) (2)
NY-ESO-1 protein-based cancer vaccines: the Melbourne experience (2005) (2)
SPECIFIC TARGETING OF TUMOR VASCULAR ENDOTHELIUM ANTIGEN (ENDOSIALIN) USING RADIOLABELED MONOCLONAL ANTIBODY FB5 (1994) (2)
Polymorphism and diversity in the Tla gene system (2004) (2)
A monoclonal antibody for terminal β-galactose. Use in analysis of glycosphingolipids (1991) (2)
Cellular immune responses against CT 7 ( MAGE-C 1 ) and humoral responses against other cancer-testis antigens in multiple myeloma patients (2005) (2)
Identification and expression analysis of novel LAGE-1 alleles with single nucleotide polymorphisms in cancer patients (2008) (2)
Studies of thoracic duct lymphocytes of mice. 3. Cell surface antigen characteristics. (1973) (2)
Targets for Immunotherapy in Epithelial Ovarian Cancer NY-ESO-1 and LAGE-1 Cancer-Testis Antigens Are Potential (2003) (2)
Cellular and humoral immune responses in patients vaccinated with HER2 protein combined with a novel nanoparticle antigen delivery system of cholesteryl hydrophobized polysacharide(CHP-HER2) (2005) (1)
Immunoreactivity to SOX-1, -2, -3 and ZIC2 antigens and correlation to survival in small cell lung cancer (SCLC). (2004) (1)
Tumor necrosis factor. (1987) (1)
IFNγ Receptor-STAT1 Signaling and Cancer Immunoediting (2003) (1)
Real time-polymerase chain reaction (PCR) improves sensitivity of lymphatic staging in colon cancer patients (2006) (1)
Clinical Trial of Radiolabelled Monoclonal Antibody (mAb) Imaging in Patients with Metastatic Renal Cancer (1987) (1)
Differential Expression of Type I MAGE in New and Relapsed Multiple Myeloma: Evidence for Association with Proliferation and Progression of Disease. (2006) (1)
Analysis of the Humoral Immune Repertoire in Patients with Cancer (1987) (1)
Passive transfer of immunity to tumor transplants in newborn mice. Abstr. (1962) (1)
Plasma-mediated leukemia cell destruction. I. Stabilization and concentration of the active fraction. Abstr. (1976) (1)
Transplanted reticulum cell sarcoma (rcs) of sjl mice. Abstr. (1969) (1)
Specificity and lyt phenotype of allospecific and tumor-specific cytotoxic t-cell lines after long term culture in interleukin 2 (il-2). Abstr. (1981) (1)
TARGETING OF TNF TO CLEAR CELL RENAL CELL CARCINOMA (2006) (1)
Tumor-reactive CD8 1 T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide V (2010) (1)
Serological Dissection of Human Breast Cancer with Mouse and Human Monoclonal Antibodies (1985) (1)
Systematic Analysis of Anti-NY-ESO-1 T Cell Responses Reveals Striking HLA-Dependent Immunodominance (2005) (1)
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4 (cid:1) and CD8 (cid:1) T cell responses in humans (2004) (1)
Advances in Brief NY-ESO-1 Expression and Immunogenicity Associated with Transitional Cell Carcinoma : Correlation with Tumor Grade 1 (2001) (1)
CT7 (MAGE-C1) is a widely expressed Cancer-Testis antigen in multiple myeloma. (2004) (1)
Efficient Synthesis of Ganglioside GM2 for Use in Cancer Vaccines. (1997) (1)
A phase I single dose escalation trial of ch806 in patients with advanced tumors expressing the 806 antigen. (2006) (1)
APhase I Trial of HumanizedMonoclonal AntibodyA 33 in Patients with Colorectal Carcinoma : Biodistribution , Pharmacokinetics , and QuantitativeTumor Uptake (2005) (1)
LOCOMOTOR ACTIVITY OF LEUKEMIC BLASTS FROM PATIENTS WITH ACUTE MYELOID LEUKEMIA AND ITS RELATIONSHIP WITH RECEPTORS FOR IgG Fc (1979) (1)
A phase I study of NY-ESO-1 overlapping peptides with or without incomplete Freund's adjuvant and poly-ICLCL vaccination of ovarian cancer patients in second or third clinical remission. (2010) (1)
Surface phenotype of nonadherent peritoneal cells effecting cell-mediated cytotoxicity in vitro for allogeneic and syngeneic murine sarcoma cells. (1976) (1)
Comparison of approaches for augmenting the serological response to the meth a antigen: cyclophosphamide is most effective. Abstr. (1983) (1)
Refunction and phosphatase activity in mouse liver. Abstr. (1960) (1)
Abstract 4519: Small cell lung cancers lack expression of argininosuccinate synthase (ASS) and are sensitive to arginine deprivation using arginine deiminase-PEG20 (ADI-PEG20) (2010) (1)
Protein and DNA-Based Vaccines With the NY-ESO-1 Antigen in Cancer Patients (2005) (1)
The arrangement of h-2 alloantigen on the cell surface. Abstr. (1969) (1)
Benign Breast Tumors NY-ESO-1 Expression and Immunogenicity in Malignant and Updated (2004) (1)
T Cells + in CD8 Growth Associated with Apoptosis Induction Peptide Vaccine Induces Enhanced Tumor (2010) (1)
Host Immune Responses Against CT Antigens in Multiple Myeloma Patients. (2006) (1)
Human Tumor Necrosis Factor (LuKII): Recent Developments (1986) (1)
SEROLOGICAL DEFINITION OF CELL SURFACE ANTIGENS OF MOUSE LEUKEMIA (1978) (1)
Synergistic therapeutic activity of chimeric G250-TNF and IFNγ for the treatment of renal cell cancer (2008) (1)
Expression of melanocyte differentiation antigens Melan-A and tyrosinase in Clear Cell Sarcomas (2002) (0)
High-Molecular-Weight Glycoproteins of Human Teratocarcinoma Defined by Monoclonal Antibodies to Carbohydrate Determinants 1 (2006) (0)
Activation by Protein Vaccination Patients and Healthy Individuals and Their T Cells in Cancer + MAGE-A3-Specific CD4 Characterization of Preexisting (2009) (0)
Delayed Hypersensitivity and Tumor Specific Immunity (1969) (0)
A monoclonal antibody which specifically binds to vascularized tumorendothelium and uses thereof (1993) (0)
Identification of the MAGE-I gene product by monoclonal and polyclonal antibodies (2004) (0)
THE RENAISSANCE OF CANCER IMMUNOSURVEILLANCE IFN-γ , Perforin , and Lymphocytes in Tumor (2004) (0)
For a fibroblast activation protein-encoding nucleic acid and uses it (1995) (0)
Suppression and Promotion Cancer Immunoediting : Integrating Immunity ' s Roles in Cancer (2014) (0)
Renal Cell Carcinomas Specific Region of the Human Proximal Tubule and Subsets Analysis of a Mouse Monoclonal Antibody That Reacts with a Updated (2006) (0)
In vivo antigen delivery by a Salmonella type III secretion system for therapeutic cancer vaccine (2006) (0)
Antigenic Modulation* *The author's work is supported by NCI grant CA 08748 and a grant from the John A. Hartford Foundation, Inc. (1970) (0)
Large-scale production and partial purification of single-chain variable domain fragment antibody in Pichia pastoris (2003) (0)
Specific Active Immunization Against Cell Surface Antigens of Human Malignant Melanoma: Development of an Approach (1981) (0)
Human renal cancer cell surface antigens defined by mouse monoclon- al antibodies. Abstr. (1981) (0)
CANCER DEFINED BY AUTOLOGOUS TYPING (1979) (0)
Similarities between Transplantation Antigens on Methylcholanthrene‐Induced Sarcomas and T‐Cell Regulatory Molecules (1983) (0)
Ex vivo correlation of antigen expression with uptake of 124I-huA33 in humans (2008) (0)
A103 andT311: two new monoclonal antibodies against the Melan-A (MART-1) and tyrosinase antigens for use on formalin-fixed paraffin-embedded tissues (1997) (0)
Antibody Reactivity to Cell Surface and IntraceUular Antigens (2003) (0)
Cholanthrene-induced sarcomas bind to t cell regulatory molecules. Abstr. (1982) (0)
SOX2 antibody responses in patients with various tumor types and SCLC with and without paraneoplastic neurologic syndromes. (2006) (0)
ANTIGENIC STRUCTURE OF CELL SURFACES and leukemic (2003) (0)
Treatment of Malignant Melanoma with a Mouse Monoclonal IgG3 Antibody Detecting the Ganglioside GD3 (1986) (0)
MAGE-A3 Inhibits p53 and Promotes Proliferation and Survival in Multiple Myeloma. (2009) (0)
Serological identification proteins as highly immur antigens in small cell lun (2016) (0)
Responses to Tumor Antigen NY-ESO-1 T Cell + and CD 4 + Naturally Occurring CD 8 Striking Immunodominance Hierarchy of (2006) (0)
Tumors by CD 4 Tumor Antigen for Direct Recognition of Peptide-Selective Presentation of Cytosolic Heat Shock Protein 90-Mediated Old and (2012) (0)
Sjl/j disease, preneoplastic and neoplastic phases. Abstr. (1969) (0)
Cell surface antigens of normal and neoplastic lymphoid cells. (1971) (0)
Analysis of Spontaneous Vs. Vaccine-Induced Antibody Responses Against Cancer-Testis Antigen MAGE-A3 in Cancer Patients (2011) (0)
Tumor antigen NY-CO-58/KIF2C is strongly overexpressed in a variety of human cancers and evokes spontaneous T cell responses (2008) (0)
Epitope peptides EGF receptor and uses thereof (2005) (0)
A method to detect the presence of cancer in a sample to be determined by detection of the expression of a SSX-2 gene and peptide thereof (1999) (0)
An isolated, dimeric fibroblast activating protein alpha, and applications thereof (1997) (0)
Process development and production of cGMP grade Melan-A for cancer vaccine clinical trials. (2013) (0)
Generation of human monoclonal a cellular antigens (hybridoma/cell-surface antigens/intracellular antigens/cancer imnm (2016) (0)
Distinctive Expression of Cancer/Testis-X Antigens in a Subset of ER Negative Breast Carcinomas. (2009) (0)
Effects ofDialyzable Transfer Factor inPatients withBreast Cancer (1974) (0)
Isolated, nucleic acid molecules for cancer-associated antigens encoding antigenic per se and their applications (2000) (0)
Vaccination With MAGE-3 Protein Induces A Potent Immune Response in A Healthy Donor Which Can Be Adoptively Transferred to A Multiple Myeloma Patient and Boosted by Further Vaccination (2005) (0)
Anticorps recombines humanises anti-lk26 (1995) (0)
Anticorps humanises recombines anti-lewis y (1995) (0)
Adjuvant Using TLR 7 Agonist Imiquimod as Vaccine Patients with Full-Length NY-ESO-1 Protein Immunization of Malignant Melanoma (2008) (0)
SOME BIOCHEMICAL P ROPERTIES OF THYMUS LEUKEMIA ANTIGENS SOLUBILIZED FROM CELL MEMBRANES BY (1973) (0)
Cancer immunology. (1977) (0)
Recombinant humanized antibody against Lewis y (1995) (0)
Abstract 2441: An innovative treatment modality of antibody therapy against intracellular tumor antigens (2010) (0)
vector T cells by bacterial + Induction of regulatory T cellresistant helper CD4 (2008) (0)
DEVELOPMENT OF AN EFFECTIVE ANTI-TUMOUR AGENT FROM THE MONOCLONAL ANTIBODY A33 (1994) (0)
HLA-DP 4 expression and immunity to NY-ESO-1 : correlation and characterization of cytotoxic CD 4 + CD 25-CD 8-T cell clones (2004) (0)
Cancer Immunity (16 May 2007) Vol. 7 Suppl.1, p. 2 (2005) (0)
Phase I study of CHP-HER2 polyvalent cancer vaccine, HER2 protein combined with a novel nanoparticle antigen delivery system of cholesteryl hydrophobized polysaccharides (2005) (0)
Surface markers of neuroectoderm-derived human tumors: In vitro models of cellular differentiation (1985) (0)
Macrophage stimulation of human ovarian cancer cells in vitro (1980) (0)
QS320. Anti-Lewis Y Antibody As a Novel Target for Gastric Adenocarcinoma (2008) (0)
BORIS, a novel cancer-testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer (2005) (0)
Tumor-Reactive CTL Analogues Capable of Improved Stimulation Identification of NY-ESO-1 Peptide and Vincenzo (2000) (0)
Abstract 5615: Effects of corticosteroids on tumor immunity induced by anti-CTLA-4 mAb therapy in a mouse model (2010) (0)
Serologie Approaches to the Study of Cancer in Animals and in Man (2006) (0)
Monoclonal antibody specifically directed against vascular endothelzellartigen endoglyx-1, which uses antigen itself and its (1995) (0)
A relationship between a serologically defined tumor specific surface antigen (tssa) and the tumor associated transplantation antigen (tata) found in the cytosol of balb/c sarcoma meth a. Abstr. (1981) (0)
Polypetide mediator network (1987) (0)
T1915 Anti-Lewis Y Antibody As a Novel Target for Pancreatic Adenocarcinoma (2008) (0)
Cell Surface Molecules of Human Melanoma (2007) (0)
Establishment and Characterization of Human Renal Cancer and Normal Kidney Cell Lines 1 (2006) (0)
Phase I safety and immunogenicity study of NY-ESO-1b peptide and Montanide ISA-51 vaccination of patients with ovarian cancer (OC) in high risk first remission. (2006) (0)
Genetic engineering of T cells with receptors from NY-ESO-1-specific tumor-recognizing CD4+ T cell as a novel approach for adoptive T cell therapy (2015) (0)
Heterogeneity of t cells. Different representations of ly alloan- tigens on killer cells and helper cells. (1975) (0)
Cancer Immunity (12 January 2006) Vol. 6, p. 2 (2005) (0)
Expression of Epidermal Growth Factor Receptor in Human Cultured Cells and Tissues: Relationship to Cell Lineage and Stage of Differentiation1 (2006) (0)
Targets for Passive Immunotherapy Intracellular Tumor-Associated Antigens Represent Effective (2012) (0)
Monoclonal antibodies and immobilized antibodies (1987) (0)
Abstract 5325: Inhibition of CD4+CD25+ regulatory T cell suppression to anti-tumor responses by OK-432 (lyophilized Streptococcus pyogenes) (2010) (0)
Recombinant humanized FB5 antibodies to (1995) (0)
Nucleic acid molecules, proteins and peptides, which are in connection with colon cells and colon-cancer cells (1996) (0)
ANTIGENS OF LEUKF, MIAS INDUCED BY NATURAT.T.Y OCCURRING MURINE LEUKEMIA VIRUS: THEIR RELATION TO THE ANTIGENS OF GROSS VIRUS AND OTHER MURINE (2003) (0)
Peptide Vaccination T Cells following + on Low/High-Avidity CD4 Regulatory T Cells + CD25+ Influence of CD4 (2006) (0)
Broad Antigen Specificity T Cell Responses + and CD 4 + Human CD 8 Receptor or DEC-205 In Vitro Elicits Dual Antibody-Targeted NY-ESO-1 to Mannose (2010) (0)
Vaccinationwith Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR 52 b-restricted CD 4 + TCell Responses with a Conserved TCell Receptor Repertoire (2009) (0)
Role of academia, government and pharmaceutical industry in early-phase clinical trials of novel cancer immunotherapies (2005) (0)
Detection of epidermal growth factor receptor (EGFr) on cultured human cell using monoclonal antibodies (mAbs): EGFr is a differentiation antigen (Ag) of cultured melanoma (1985) (0)
Melanoma tumor antigen and autologous antibody (1986) (0)
The phagocytosis of tumor cells in vitro. Abstr. (1963) (0)
Specificity analysis of two new mouse monoclonal antibodies reactive with prostate cancer (1987) (0)
Protein alpha activating dimeric isolated fibroblasts, and uses thereof. (1997) (0)
A method for purifying a proteinaceous physiologically active substance having antitumor activity and the proteinaceous physiologically active substance purified by this procedure (1982) (0)
TL.4, A leukemia-specific antigen coded by the cell genome. Abstr. (1970) (0)
Complement and Feline Leukemia (1976) (0)
Complement in the phenomenon. (1973) (0)
Cancer is a somaticcell pregnancy (2007) (0)
Sarcoma Cells Immunogenic Properties of Soluble Cytosol Fractions of Meth A (2006) (0)
Method for purifying a protein substance endowed with antitumor activity (1982) (0)
THE HUMORAL IMMUNE RESPONSE TO HUMAN CANCER1 (1985) (0)
blood donors Blood donor Diagnosis Extent of disease Age Sex History of transfusion Carcinoma of bladder Carcinoma of bladder and 6 other primary tumors over past 50 yr Melanoma Carcinoma of bladder Carcinoma of bladder Melanoma (2007) (0)
Gene expression profile pregnancy reveals similar genetic program in cancer and placenta development: identification of novel targets for cancer immunotherapy (2010) (0)
SURFACE ANTIGENS OF CELLS OF THE II ~ (2003) (0)
Colon cell and colon cancer cell associated nucleic acid molecules, protein and peptides (1997) (0)
Anticorps humains recombines diriges contre l'antigene b de lewis (1996) (0)
Tissue-specific ING 1 Transcripts and a Homologue Gene Product Are Breast Cancer Antigens : Characterization of Tumor Suppressor Gene ING 1 Cancer-Testis Antigens and Updated (1999) (0)
Cancer Immunity (26 August 2009) Vol. 9, p. 6 (2005) (0)
Expression of Lewis3, Lewis", X, and Y Blood Group Antigens in Human Colonie Tumors and Normal Tissue and in Human Tumor-derived Cell Lines1 (2006) (0)
Phase I study of humanised antibody A33 (Hua33) in patients with colorectal carcinoma - preliminary whole body clearance and tumour dosimetry (1999) (0)
[Leukemia-specific antigens in mice--its relation to viral antigens]. (1966) (0)
Hypocomplementemia in Feline Lymphosarcoma (1978) (0)
Immunological Effects and Clinical Activity Toxins) in Patients with NY-ESO-1 Expressing Cancers: Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's (2012) (0)
A34 — Expression of a novel differentiation antigen of the stomach mucosa on a protein level (2004) (0)
Recombinant humanized anti-lewis antibodies and. (1995) (0)
Communication of scientific information at a cancer research institute. (1974) (0)
Cancer Immunity 3:19 (2003)-ARTICLE (2003) (0)
Subpopulations of cytotoxic t cells with different surface phenotypes. Abstr. (1975) (0)
NY-ESO-1 protein formulated With ISCOMATRIX™ adjuvant induces a broad-based immune response involving high titers of antibody, CD4+ and CD8+ T-cell responses (2003) (0)
Chimeric G250 in Metastatic Renal Cancer (2004) (0)
[FACTORS WHICH PLAY A ROLE IN THE PRODUCTION OF ISOANTIBODIES IN MICE. SEX, THE COURSE OF IMMUNIZATION, SPLENECTOMY, AND SURGICAL SHOCK]. (1964) (0)
Improving antibodies by evolution and engineering (2003) (0)
Definition of an antigen shared by herpesviruses and oncornaviruses. (1978) (0)
Effect of serum from bcg-endotoxin treated mice on immune parameters in vitro. Abstr. (1975) (0)
Characteristics of a tumor rejection antigen from the cytosol fraction of a chemically induced sarcoma. Abstr. (1980) (0)
Abstract 4741: Therapeutic efficacy of a human-derived antibody against cancer-testis antigen NY-ESO-1 (2011) (0)
MAGE-3 Protein in Lung Cancer Patients Vaccine-Induced CD4+ T Cell Responses to (2013) (0)
Clinical Cancer esearch ing , Diagnosis , Prognosis essment of Vaccine-Induced CD 4 T Cell Responses to the-143 Immunodominant Region of the Tumor-Specific R igen NY-ESO-1 Using DRB 1 * 0101 Tetramers (2010) (0)
Antibody targeting of epithelial carcinoma-associated fibroblast activation protein blocks cellular proliferation, migration, and invasion. (2010) (0)
Specificity analysis of mouse mono4 surface antigens of human renal ca (differentiation antigens/immunopathology/adenosine deaminase bin (2016) (0)
Monoclonal antibodies against human kidney cancer antigens and procedures. (1984) (0)
Cancer-associated nucleic acid and proteins (1998) (0)
Scientific category: Immunobiology Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma (2016) (0)
Expression of Epidermal Growth Factor Receptor in Human Cultured Cells and Tissues : Relationship to Cell Lineage and Stage of Differentiation 1 (2006) (0)
A NEW CELL SURFACE ANTIGEN OF MOUSE LEUKEMIA DEFINED BY NATURALLY OCCURRING ANTIBODY RELATIONSHIP TO MURINE LEUKEMIA VIRUS* (2003) (0)
induce systemic immunity following allogeneic stem cell transplantation Cancer-testis antigens are commonly expressed in multiple myeloma and (2013) (0)
Specific cytogenetic abnormality (trisomy of chromsome 15) in akr mouse leukemia. Abstr. (1975) (0)
MAGE-3 Protein in Lung Cancer Patients T Cell Responses to + Vaccine-Induced CD4 (2004) (0)
Characterization of a cDNA encoding a 34-kDa Purkinje neuron protein recognized by sera from patients with paraneoplastic cerebellar degeneration ( tumor antigens / remote effects of cancer / autoantibodies / autoimmunity ) (0)
Phase I trial of huA33 antibody plus 5-fluorouracil (5FU), leucovorin, and oxaliplatin in patients with metastatic colorectal cancer [LUD2003–005] (2007) (0)
Type I MAGE Proteins: Novel Markers of Proliferation in Multiple Myeloma Progenitor Cells. (2005) (0)
Tumor immunity and immunosurveillance, session 2 (WS-093b) Chairpersons: Takashi Nishimura, Jean-Pierre Abastado (2010) (0)
Uptake of 124I-huA33 in colorectal tumors in patients assessed by post-surgical digital autoradiography (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Lloyd j. Old?

Lloyd j. Old is affiliated with the following schools:

Lloyd j. Old's Academic­Influence.com Rankings

Lloyd j. Old's Degrees

Why Is Lloyd j. Old Influential?

Lloyd j. Old's Published Works

Published Works

What Schools Are Affiliated With Lloyd j. Old?

Lloyd j. Old's AcademicInfluence.com Rankings